Table 1.
Study cohort characteristics.
| Study Cohort (n = 67) | |
|---|---|
| Age (years) | 57 ± 17 |
| Male, n (%) | 42 (63) |
| BMI (kg/m2) | 30 ± 6 (n = 57) |
| Race / Ethnicity, n (%) | |
| Asian | 2 (3) |
| Black | 3 (5) |
| Hispanic or Latino | 41 (61) |
| White | 15 (22) |
| Other or more than one race | 5 (8) |
| Medical Comorbidities, n (%) | |
| Cardiovascular Disease | 12 (18) |
| Heart Failure | 9 (13) |
| Coronary artery disease | 8 (12) |
| Prior PCI | 0 (0) |
| Prior CABG | 3 (5) |
| PAD | 6 (9) |
| Hypertension | 27 (40) |
| Diabetes Mellitus | 23 (34) |
| Obesity | 43 (64) |
| Stroke | 5 (8) |
| Atrial Fibrillation / Flutter | 10 (15) |
| Chronic Kidney Disease | 7 (10) |
| Asthma | 4 (6) |
| Chronic Obstructive Pulmonary Disease | 1 (2) |
| Active Smoker | 2 (3) |
| Malignancy | 7 (10) |
| Prior Organ Transplant | 2 (3) |
| Rheumatologic Disease | 5 (8) |
| HIV | 2 (3) |
| Home Medications | |
| ACE-I / ARB | 26 (39) |
| Beta Blocker | 13 (19) |
| Diuretic | 15 (22) |
| MRA | 2 (3) |
| Aspirin | 25 (37) |
| Statin | 18 (27) |
| NSAIDs | 13 (19) |
| Initial Labs | |
| Creatinine (mg/dL) | 0.9 [0.7–1.2] |
| Estimated GFR (mL/min/1.73 m2) | 88 ± 47 |
| hsTnT, Initial (ng/L) | 18 [6–47] (n = 35) |
| hsTnT, Peak (ng/L) | 21 [7–66](n = 47) |
| hsTnT, Time of Echocardiogram (ng/L) | 48 [19–251] (n = 15) |
| NT-proBNP (pg/mL) | 1321 [230–5472] (n = 38) |
| D-dimer-HS (ng/mL) | 743 [319–4563] (n = 45) |
| Procalcitonin (ng/mL) | 0.3 [0.1–1.2] (n = 56) |
| C-Reactive Protein (mg/dL) | 12 [5–24] (n = 47) |
| Clinical Outcomes | |
| Presentation | |
| Emergency Department, n (%) | 32 (48) |
| Transfer, n (%) | 14 (21) |
| Unknown, n (%) | 21 (31) |
| Hospital Admission, n (%) | 66 (99) |
| Admission for COVID-19, n (%) | 62 (93) |
| Required ICU, n (%) | 56 (84) |
| Required Intubation / Ventilator, n (%) | 50 (75) |
| Required V-V ECMO, n (%) | 16 (24) |
| Renal Failure Requiring CRRT, n (%) | 13 (19) |
| Length of Stay (Days) | 23 [14–36] |
| ICU Length of Stay (Days) | 45 [16–88] (n = 56) |
| Disposition, n (%) | |
| Death | 22 (33) |
| Discharged (non-healthcare facility) | 22 (33) |
| Acute care facility | 15 (22) |
| SNF / Rehab | 7 (10) |
| Remain Admitted | 1 (2) |
Values are presented as mean ± standard deviation, median [IQR] or n (%). ACE-I = angiotensin-converting enzyme inhibitor, ARB = angiotensin-receptor blocker, BMI = Body Mass Index, CABG = coronary artery bypass graft surgery, CRRT = continuous renal replacement therapy, GFR = glomerular filtration rate, hsTnT = = high-sensitivity troponin T, ICU = intensive care unit, LTAC = long-term acute care facility, MRA = mineralcorticoid-receptor antagonist, NSAID = non-steroidal anti-inflammatory drug, NT-proBNP = brain-terminal B-type natriuretic peptide, PAD = peripheral arterial disease, PCI = percutaneous coronary intervention, SNF = skilled nursing facility, V-V ECMO = venovenous extra-corporeal membranous oxygenation.